https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52945 Wed 28 Feb 2024 16:18:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46451 Wed 23 Nov 2022 14:17:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13797 Wed 11 Apr 2018 11:18:00 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31352 Wed 10 Nov 2021 15:04:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24323 T (n=18) and MC_T/CPA3 (mRNA expression of TPSAB1 and CPA3; n=29) subtypes were identified, as well as a group without mast cell gene expression (n=8). The MC_T/CPA3 subtype had elevated exhaled nitric oxide fraction, sputum eosinophils, bronchial sensitivity and reactivity, and poorer asthma control. This was accompanied by upregulation of 13 genes. Multivariable logistic regression identified CPA3 (OR 1.21, p=0.004) rather than TPSAB1 (OR 0.92, p=0.502) as a determinant of eosinophilic asthma. The MC_T/CPA3 subtype had a better clinical response and reduced signature gene expression with corticosteroid treatment. Sputum mast cell subtypes of asthma can be defined by a molecular phenotyping approach. The MC_T/CPA3 subtype demonstrated increased bronchial sensitivity and reactivity, and signature gene expression, which was associated with airway eosinophilia and greater corticosteroid responsiveness.]]> Wed 09 Mar 2022 15:59:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50859 Wed 09 Aug 2023 10:13:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48671 Tue 28 Mar 2023 10:25:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53957 Tue 23 Jan 2024 10:53:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43418 Tue 20 Sep 2022 08:26:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50999 Tue 15 Aug 2023 11:52:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47057 Tue 13 Dec 2022 15:32:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53621 Tue 12 Dec 2023 15:19:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38777 Tue 08 Feb 2022 12:17:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24324 Tropheryma whipplei and Haemophilus influenzae in sputum. Adults with neutrophilic asthma had reduced bacterial diversity and species richness. Tropheryma was identified and confirmed with real-time PCR in 12 (40%) participants. Haemophilus occurred most often in a group of younger atopic males with an increased proportion of neutrophils. PCR confirmed the presence of H. influenzae in 35 (76%) participants with poorly controlled asthma. There are phenotype-specific alterations to the airway microbiome in asthma. Reduced bacterial diversity combined with a high prevalence of H. influenzae was observed in neutrophilic asthma, whereas eosinophilic asthma had abundant T. whipplei.]]> Thu 28 Oct 2021 13:02:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41158 Thu 28 Jul 2022 09:27:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30788 Thu 27 Jan 2022 15:58:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:416 Thu 25 Jul 2013 09:10:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:407 Thu 25 Jul 2013 09:09:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45652 Thu 23 Mar 2023 13:58:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31150 Thu 17 Feb 2022 09:28:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46840 Thu 01 Dec 2022 15:50:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1890 Sat 24 Mar 2018 08:33:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:2984 1 week) supplementation trials have been promising. However, the development of techniques to study isoprostanes in airway­lining fluid pave the way for further studies investigating the potential for antioxidant supplements to be used as routine therapy in asthma.]]> Sat 24 Mar 2018 08:27:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14643 Sat 24 Mar 2018 08:20:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12782 Sat 24 Mar 2018 08:17:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13283 Sat 24 Mar 2018 08:15:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13284 Sat 24 Mar 2018 08:15:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13282 Sat 24 Mar 2018 08:15:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11169 Sat 24 Mar 2018 08:10:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17510 Sat 24 Mar 2018 08:04:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17502 , FVC and FEF25-75% from 11654 white males and 11113 white females, aged 3-94 years, routinely tested in the pulmonary function laboratories of four tertiary hospitals. FEF75% was available in 8254 males and 7407 females. Predicted values and lower limits of normal, defined as the fifth percentile, were calculated for FEV1, FVC, FEV1/FVC ratio, FEF25-75% and FEF75% using prediction equations from the Global Lung Function Initiative. There was very little discordance in classifying test results. FEF25-75% and FEF75% were below the normal range in only 2.75% and 1.29% of cases, respectively, whereas FEV1, FVC and FEV1/FVC ratio were within normal limits. Airways obstruction went undetected by FEF25-75% in 2.9% of cases and by FEF75% in 12.3% of cases. Maximum mid-expiratory flow and flow towards the end of the forced expiratory manoeuvre do not contribute usefully to clinical decision making over and above information from FEV1, FVC and FEV1/FVC ratio.]]> Sat 24 Mar 2018 08:04:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17293 Sat 24 Mar 2018 08:01:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16918 1)/(forced) vital capacity ((F)VC) ratio below the fifth percentile and graded the severity of pulmonary function impairment using z-scores for FEV₁, which signify how many standard deviations a result is from the mean predicted value. Using the lower limit of normal for FEV₁/(F)VC and z-scores for FEV₁ of -2, -2.5, -3 and -4 to delineate severity grades of airflow limitation leads to close agreement with ATS/ERS severity classifications and removes age, sex and height related bias. The new classification system is simple, easily memorised and clinically valid. It retains previously established associations with clinical outcomes and avoids biases due to the use of per cent predicted FEV₁. Combined with the Global Lung Function prediction equations it provides a worldwide diagnostic standard, free of bias due to age, height, sex and ethnic group.]]> Sat 24 Mar 2018 08:00:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16919 Sat 24 Mar 2018 08:00:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21544 Sat 24 Mar 2018 07:50:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28998 Sat 24 Mar 2018 07:29:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26767 Sat 24 Mar 2018 07:24:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28201 Sat 24 Mar 2018 07:23:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4310 Sat 24 Mar 2018 07:22:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4324 Sat 24 Mar 2018 07:22:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22218 Sat 24 Mar 2018 07:17:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23803 Sat 24 Mar 2018 07:12:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39032 Mon 29 Jan 2024 17:51:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46962 Il22^−/−) mice. CS-induced airway remodelling and emphysema-like alveolar enlargement did not occur in Il22^−/− mice. Il22^−/− mice had improved lung function in terms of airway resistance, total lung capacity, inspiratory capacity, forced vital capacity and compliance. These data highlight important roles for IL-22 and its receptors in human COPD and CS-induced experimental COPD.]]> Mon 12 Dec 2022 14:27:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44178 Mon 10 Oct 2022 10:20:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33084 Fri 24 Aug 2018 15:43:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40118 Fri 22 Jul 2022 13:48:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40097 Fri 22 Jul 2022 13:41:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34249 Fri 22 Feb 2019 16:55:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47445 Fri 20 Jan 2023 14:08:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46329 Fri 18 Nov 2022 09:59:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40156 Fri 15 Jul 2022 09:51:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47321 Fri 13 Jan 2023 11:06:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47318 + CD138⁺ plasma cells (PCs). Interestingly, high levels of CD138⁺ cells were also identified in the lung tissue of patients with IPF, consistent with the mouse model. Treatment of mice with bortezomib, which depletes PCs, reduced the level of Blm-induced lung fibrosis, implicating PCs as important effector cells in the development and progression of pulmonary fibrosis.]]> Fri 13 Jan 2023 11:00:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46107 −2) versus healthy-weight (BMI <25 kg·m⁻²) subjects with asthma. Design Databases including CINAHL (Cumulative Index to Nursing and Allied Health Literature), Cochrane, Embase and MEDLINE were searched up to July 2019 for English-language studies that recorded medication use or dose in obese and healthy-weight adults with asthma. A critical appraisal checklist was utilised for scrutinising methodological quality of eligible studies. Meta-analysis was performed and heterogeneity was examined with the use of the Chi-squared test. This review was conducted based on a published protocol (www.crd.york.ac.uk/PROSPERO CRD42020148671). Results Meta-analysis showed that obese subjects are more likely to use asthma medications, including short-acting β2-agonists (OR 1.75, 95% CI 1.17–2.60; p=0.006, I²=41%) and maintenance oral corticosteroids (OR 1.86, 95% CI 1.49–2.31; p<0.001, I2=0%) compared to healthy-weight subjects. Inhaled corticosteroid (ICS) dose (µg·day⁻¹) was significantly higher in obese subjects (mean difference 208.14, 95% CI 107.01–309.27; p<0.001, I²=74%). Forced expiratory volume in 1 s (FEV₁) % predicted was significantly lower in obese subjects (mean difference −5.32%, 95% CI −6.75–−3.89; p<0.001, I²=42%); however, no significant differences were observed in FEV₁/forced vital capacity (FVC) ratio between groups. Conclusions We found that obese subjects with asthma have higher use of all included asthma medication classes and higher ICS doses than healthy-weight asthma subjects, despite lower FEV₁ and a similar FEV₁/FVC %. A better understanding of the factors driving increased medication use is required to improve outcomes in this subgroup of asthmatics.]]> Fri 11 Nov 2022 15:35:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46066 Fri 11 Nov 2022 14:45:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33714 Fri 07 Dec 2018 16:47:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24513 Fri 01 Apr 2022 09:29:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36583 Fri 01 Apr 2022 09:23:30 AEDT ]]>